Treatment algorithm in patients with ovarian cancer

Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemothera...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Facts, views & vision in ObGyn views & vision in ObGyn, 2020-10, Vol.12 (3), p.227-239
Hauptverfasser: Vergote, I, Denys, H, De Greve, J, Gennigens, C, Van De Vijver, K, Kerger, J, Vuylsteke, P, Baurain, J F
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 239
container_issue 3
container_start_page 227
container_title Facts, views & vision in ObGyn
container_volume 12
creator Vergote, I
Denys, H
De Greve, J
Gennigens, C
Van De Vijver, K
Kerger, J
Vuylsteke, P
Baurain, J F
description Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7580261</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2456409487</sourcerecordid><originalsourceid>FETCH-LOGICAL-l240t-89bc1f85c929bf414aa1a1b89262c9291a555fd4cfa24515e0aa22d305196ab13</originalsourceid><addsrcrecordid>eNpVUMtqwzAQNKWlCWl-ofjYi0FaSbZ0KZTQRyDQS3oWa0V2VGQ7le2U_n2VR0u7lx1md2aHvUimkEuecWDkMmLCICOcykky7_t3EkvSAoS6TiaMUWC5KqYJWweLQ2PbIUVfd8EN2yZ1bbrDwUWyTz8jk3Z7DA7b1GBrbLhJrir0vZ2f-yx5e3pcL16y1evzcvGwyjxwMmRSlYZWUhgFqqw45YgUaSkV5HDgKAohqg03FQIXVFiCCLBhRFCVY0nZLLk_-e7GsrEbE_ME9HoXXIPhS3fo9P9J67a67va6EJJAfjBgJwPvbG11F0qn93AUHvHoa41Gl1ZD_JwGAYIeVHfns6H7GG0_6Mb1xnqPre3GXsewOSeKyyKu3v5N-Bvt57_sGwnleE4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2456409487</pqid></control><display><type>article</type><title>Treatment algorithm in patients with ovarian cancer</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Vergote, I ; Denys, H ; De Greve, J ; Gennigens, C ; Van De Vijver, K ; Kerger, J ; Vuylsteke, P ; Baurain, J F</creator><creatorcontrib>Vergote, I ; Denys, H ; De Greve, J ; Gennigens, C ; Van De Vijver, K ; Kerger, J ; Vuylsteke, P ; Baurain, J F</creatorcontrib><description>Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium.</description><identifier>ISSN: 2032-0418</identifier><identifier>ISSN: 2684-4230</identifier><identifier>EISSN: 2684-4230</identifier><identifier>PMID: 33123697</identifier><language>eng</language><publisher>Belgium: Universa Press</publisher><subject>Epithelial ovarian cancer ; genetic testing ; Human health sciences ; Oncologie ; oncology ; Sciences de la santé humaine ; targeted agents ; treatment algorithm ; Viewpoint Paper</subject><ispartof>Facts, views &amp; vision in ObGyn, 2020-10, Vol.12 (3), p.227-239</ispartof><rights>Copyright © 2020 Facts, Views &amp; Vision.</rights><rights>Copyright © 2020 Facts, Views &amp; Vision</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580261/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7580261/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33123697$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vergote, I</creatorcontrib><creatorcontrib>Denys, H</creatorcontrib><creatorcontrib>De Greve, J</creatorcontrib><creatorcontrib>Gennigens, C</creatorcontrib><creatorcontrib>Van De Vijver, K</creatorcontrib><creatorcontrib>Kerger, J</creatorcontrib><creatorcontrib>Vuylsteke, P</creatorcontrib><creatorcontrib>Baurain, J F</creatorcontrib><title>Treatment algorithm in patients with ovarian cancer</title><title>Facts, views &amp; vision in ObGyn</title><addtitle>Facts Views Vis Obgyn</addtitle><description>Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium.</description><subject>Epithelial ovarian cancer</subject><subject>genetic testing</subject><subject>Human health sciences</subject><subject>Oncologie</subject><subject>oncology</subject><subject>Sciences de la santé humaine</subject><subject>targeted agents</subject><subject>treatment algorithm</subject><subject>Viewpoint Paper</subject><issn>2032-0418</issn><issn>2684-4230</issn><issn>2684-4230</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNpVUMtqwzAQNKWlCWl-ofjYi0FaSbZ0KZTQRyDQS3oWa0V2VGQ7le2U_n2VR0u7lx1md2aHvUimkEuecWDkMmLCICOcykky7_t3EkvSAoS6TiaMUWC5KqYJWweLQ2PbIUVfd8EN2yZ1bbrDwUWyTz8jk3Z7DA7b1GBrbLhJrir0vZ2f-yx5e3pcL16y1evzcvGwyjxwMmRSlYZWUhgFqqw45YgUaSkV5HDgKAohqg03FQIXVFiCCLBhRFCVY0nZLLk_-e7GsrEbE_ME9HoXXIPhS3fo9P9J67a67va6EJJAfjBgJwPvbG11F0qn93AUHvHoa41Gl1ZD_JwGAYIeVHfns6H7GG0_6Mb1xnqPre3GXsewOSeKyyKu3v5N-Bvt57_sGwnleE4</recordid><startdate>20201008</startdate><enddate>20201008</enddate><creator>Vergote, I</creator><creator>Denys, H</creator><creator>De Greve, J</creator><creator>Gennigens, C</creator><creator>Van De Vijver, K</creator><creator>Kerger, J</creator><creator>Vuylsteke, P</creator><creator>Baurain, J F</creator><general>Universa Press</general><scope>NPM</scope><scope>7X8</scope><scope>Q33</scope><scope>5PM</scope></search><sort><creationdate>20201008</creationdate><title>Treatment algorithm in patients with ovarian cancer</title><author>Vergote, I ; Denys, H ; De Greve, J ; Gennigens, C ; Van De Vijver, K ; Kerger, J ; Vuylsteke, P ; Baurain, J F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-l240t-89bc1f85c929bf414aa1a1b89262c9291a555fd4cfa24515e0aa22d305196ab13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Epithelial ovarian cancer</topic><topic>genetic testing</topic><topic>Human health sciences</topic><topic>Oncologie</topic><topic>oncology</topic><topic>Sciences de la santé humaine</topic><topic>targeted agents</topic><topic>treatment algorithm</topic><topic>Viewpoint Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vergote, I</creatorcontrib><creatorcontrib>Denys, H</creatorcontrib><creatorcontrib>De Greve, J</creatorcontrib><creatorcontrib>Gennigens, C</creatorcontrib><creatorcontrib>Van De Vijver, K</creatorcontrib><creatorcontrib>Kerger, J</creatorcontrib><creatorcontrib>Vuylsteke, P</creatorcontrib><creatorcontrib>Baurain, J F</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Université de Liège - Open Repository and Bibliography (ORBI)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Facts, views &amp; vision in ObGyn</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vergote, I</au><au>Denys, H</au><au>De Greve, J</au><au>Gennigens, C</au><au>Van De Vijver, K</au><au>Kerger, J</au><au>Vuylsteke, P</au><au>Baurain, J F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment algorithm in patients with ovarian cancer</atitle><jtitle>Facts, views &amp; vision in ObGyn</jtitle><addtitle>Facts Views Vis Obgyn</addtitle><date>2020-10-08</date><risdate>2020</risdate><volume>12</volume><issue>3</issue><spage>227</spage><epage>239</epage><pages>227-239</pages><issn>2032-0418</issn><issn>2684-4230</issn><eissn>2684-4230</eissn><abstract>Most ovarian cancer patients are diagnosed only at advanced stages when survival outcomes are worse, andwhen therapeutic decisions might prove challenging. The fundamental treatment for women with ovarian cancerincludes debulking surgery whenever possible and appropriate systemic therapy (chemotherapy, targeted andantiangiogenic agents). In the last few years, knowledge about histological and molecular characteristics of ovariancancer subtypes and stages has increased considerably. This has enabled the development and improvement ofseveral options for the diagnosis and treatment of ovarian cancer in a patient-tailored approach. Accordingly,therapeutic decisions are guided by the characteristics of the patient and the tumour, especially the molecularfeatures of the cancer subtype and disease stage. Particularly relevant are the advances in early genetic testing ofgermline and somatic mutations involved in DNA repair, and the clinical development of targeted agents. In orderto implement the best individual medical strategies, in this article, we present an algorithm of treatment options,including recently developed targeted agents, for primary and recurrent ovarian cancer patients in Belgium.</abstract><cop>Belgium</cop><pub>Universa Press</pub><pmid>33123697</pmid><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2032-0418
ispartof Facts, views & vision in ObGyn, 2020-10, Vol.12 (3), p.227-239
issn 2032-0418
2684-4230
2684-4230
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7580261
source PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Epithelial ovarian cancer
genetic testing
Human health sciences
Oncologie
oncology
Sciences de la santé humaine
targeted agents
treatment algorithm
Viewpoint Paper
title Treatment algorithm in patients with ovarian cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T14%3A09%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20algorithm%20in%20patients%20with%20ovarian%20cancer&rft.jtitle=Facts,%20views%20&%20vision%20in%20ObGyn&rft.au=Vergote,%20I&rft.date=2020-10-08&rft.volume=12&rft.issue=3&rft.spage=227&rft.epage=239&rft.pages=227-239&rft.issn=2032-0418&rft.eissn=2684-4230&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E2456409487%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2456409487&rft_id=info:pmid/33123697&rfr_iscdi=true